
|Articles|October 15, 2002
Head-to-head trial: Phase III study tests options for wet AMD
Fort Worth, TX-Alcon Research Ltd. is enrolling about 500 patients in a phase III study to compare the effects of anecortave acetate versus verteporfin (Visudyne, Novartis) photodynamic therapy for the treatment of wet age-related macular degeneration.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment
2
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
3
Development of maculopathy associated with systemic medications
4
Proactive strategies and sustained delivery advance glaucoma care
5

















































.png)


